Research graph
References from Targeting the <scp>EpCAM</scp> ‐ <scp>AXL</scp> axis to overcome drug resistance in lung cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2025
2025 · External reference
The prevalence of EGFR mutation in patients with non‐small cell lung cancer: a systematic review and meta‐analysis
10.18632/oncotarget.12587 · 2016 · External reference
Activation of the AXL kinase causes resistance to EGFR‐targeted therapy in lung cancer
10.1038/ng.2330 · 2012 · External reference
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR‐mutant lung cancers that lack the second‐site EGFRT790M mutation
10.1158/2159-8290.cd-12-0108 · 2012 · External reference
An ERBB1‐3 neutralizing antibody mixture with high activity against drug‐resistant HER2+ breast cancers with ERBB ligand overexpression
10.1093/jnci/djx065 · 2017 · External reference
The different mechanisms of cancer drug resistance: a brief review
10.15171/apb.2017.041 · 2017 · External reference
Highlights in resistance mechanism pathways for combination therapy
10.3390/cells8091013 · 2019 · External reference
AXL tyrosine kinases: a growing isoform family that promotes cancer pathogenesis
10.1158/0008-5472.can-24-3841 · 2025 · External reference
AXL‐driven EMT state as a targetable conduit in cancer
10.1158/0008-5472.can-17-0392 · 2017 · External reference
Epithelial‐to‐mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
10.1038/nature15748 · 2015 · External reference
AXL: shapers of tumor progression and immunosuppressive microenvironments
10.1186/s12943-024-02210-9 · 2025 · External reference
The receptor AXL diversifies EGFR signaling and limits the response to EGFR‐targeted inhibitors in triple‐negative breast cancer cells
10.1126/scisignal.2004155 · 2013 · External reference
The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond
10.1111/febs.16923 · 2024 · External reference
Extracellular proteolysis in cancer: proteases, substrates, and mechanisms in tumor progression and metastasis
10.1016/j.jbc.2024.107347 · 2024 · External reference
ADAM17‐mediated EGFR ligand shedding directs macrophage‐promoted cancer cell invasion
2022 · External reference
Nuclear signalling by tumour‐associated antigen EpCAM
10.1038/ncb1824 · 2009 · External reference
Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy
10.1016/j.oraloncology.2006.10.010 · 2007 · External reference
Loss of membranous ep‐CAM in budding colorectal carcinoma cells
10.1038/modpathol.3800733 · 2007 · External reference
The expression of ep‐CAM (17‐1A) in squamous cell cancers of the lung
10.1053/hp.2000.6711 · 2000 · External reference
Frequent high‐level expression of the immunotherapeutic target ep‐CAM in colon, stomach, prostate and lung cancers
10.1038/sj.bjc.6602924 · 2006 · External reference
Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway
10.1016/j.biocel.2013.09.008 · 2013 · External reference
Epithelial cell adhesion molecule overexpression regulates epithelial‐mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway
10.1038/s41419-017-0013-8 · 2018 · External reference
Activator protein 1 (AP‐1) contributes to EpCAM‐dependent breast cancer invasion
10.1186/bcr3070 · 2011 · External reference
EpCAM modulates NF‐kappaB signaling and interleukin‐8 expression in breast cancer
10.1158/1541-7786.mcr-12-0518 · 2013 · External reference
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival
10.1186/s12885-025-14455-8 · 2025 · External reference
Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung
2009 · External reference
CpG island methylation status in the EpCAM promoter region and gene expression
2008 · External reference
Persistent downregulation of the pancarcinoma‐associated epithelial cell adhesion molecule via active intranuclear methylation
10.1002/ijc.23476 · 2008 · External reference
A double‐negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial‐mesenchymal transition in cancer
10.1038/onc.2016.504 · 2017 · External reference
EpCAM‐mediated cellular plasticity promotes radiation resistance and metastasis in breast cancer
10.3389/fcell.2020.597673 · 2020 · External reference
Drug‐induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma
10.1007/s13402-018-0399-z · 2018 · External reference
Cancer‐associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin‐L and tumor cell invasion
10.1186/s12885-021-08239-z · 2021 · External reference
Functional implications of the dynamic regulation of EpCAM during epithelial‐to‐mesenchymal transition
10.3390/biom11070956 · 2021 · External reference
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
10.1158/0008-5472.can-04-0754 · 2004 · External reference
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis
10.1136/jcp.2011.090274 · 2011 · External reference
An epithelial‐mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
10.1158/1078-0432.ccr-12-1558 · 2013 · External reference
Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer
10.1002/ijc.25704 · 2011 · External reference
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival
10.1371/journal.pone.0001651 · 2008 · External reference
Biomarker discovery in non‐small cell lung cancer: integrating gene expression profiling, meta‐analysis, and tissue microarray validation
10.1158/1078-0432.ccr-12-1139 · 2013 · External reference
Validation of a histology‐independent prognostic gene signature for early‐stage, non‐small‐cell lung cancer including stage IA patients
10.1097/jto.0000000000000042 · 2014 · External reference
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
10.1038/nature04296 · 2006 · External reference
Prediction of recurrence‐free survival in postoperative non‐small cell lung cancer patients by using an integrated model of clinical information and gene expression
10.1158/1078-0432.ccr-07-4937 · 2008 · External reference
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung
10.1158/0008-5472.can-06-1191 · 2006 · External reference
Strengths and limitations of microarray‐based phenotype prediction: lessons learned from the IMPROVER diagnostic signature challenge
10.1093/bioinformatics/btt492 · 2013 · External reference
Identification of genes upregulated in ALK‐positive and EGFR/KRAS/ALK‐negative lung adenocarcinomas
10.1158/0008-5472.can-11-1403 · 2012 · External reference
Ectopic activation of germline and placental genes identifies aggressive metastasis‐prone lung cancers
10.1126/scitranslmed.3005723 · 2013 · External reference
Crystal structure and its bearing towards an understanding of key biological functions of EpCAM
10.1038/ncomms5764 · 2014 · External reference
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
10.18632/oncotarget.4496 · 2015 · External reference
Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T‐cell activation by EpCAM/CD3‐bispecific BiTE antibody MT110
10.4161/mabs.3.1.14193 · 2011 · External reference
AXL degradation in combination with EGFR‐TKI can delay and overcome acquired resistance in human non‐small cell lung cancer cells
10.1038/s41419-019-1601-6 · 2019 · External reference
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
10.1038/ncomms6712 · 2014 · External reference
Heparin and cancer revisited: mechanistic connections involving platelets, P‐selectin, carcinoma mucins, and tumor metastasis
10.1073/pnas.061615598 · 2001 · External reference
Lysis of tumor cells by natural killer cells in mice is impeded by platelets
1999 · External reference
EpCAM‐positive disseminated cancer cells in bone marrow impact on survival of early‐stage NSCLC patients
10.1016/j.lungcan.2022.02.008 · 2022 · External reference
Frequent EpCam protein expression in human carcinomas
10.1016/j.humpath.2003.08.026 · 2004 · External reference
Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
10.1186/s12885-015-1371-1 · 2015 · External reference
AXL signaling in cancer: from molecular insights to targeted therapies
10.1038/s41392-024-02121-7 · 2025 · External reference
AXL targeting restores PD‐1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells
10.1016/j.xcrm.2022.100554 · 2022 · External reference
The role of proteasome inhibition in nonsmall cell lung cancer
2011 · External reference
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
10.18632/oncotarget.21221 · 2017 · External reference
Incorporating bortezomib into the treatment of lung cancer
10.1158/1078-0432.ccr-07-0334 · 2007 · External reference
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
10.1038/sj.bjc.6605043 · 2009 · External reference
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
10.1182/blood-2006-10-054502 · 2007 · External reference
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
10.1073/pnas.1002985107 · 2010 · External reference
Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression
10.1631/jzus.b1900551 · 2020 · External reference
KRAS genotype correlates with proteasome inhibitor Ixazomib activity in preclinical in vivo models of colon and non‐small cell lung cancer: potential role of tumor metabolism
10.1371/journal.pone.0144825 · 2015 · External reference
Integrated safety profile of single‐agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
10.3324/haematol.2013.089334 · 2013 · External reference
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa1516282 · 2016 · External reference
Bortezomib for the treatment of hematologic malignancies: 15 years later
10.1007/s40268-019-0269-9 · 2019 · External reference
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non‐small cell lung cancer
10.1158/0008-5472.can-09-3763 · 2010 · External reference
